This Special Issue of Cancers (Basel) is mainly dedicated to selecting papers from the talks given during the first Joint Meeting on Lung Cancer (JMLC) between the MD Anderson Cancer Center (Houston, Texas USA) and the Hospital University Federation (HUF) OncoAge (University Côte d’Azur, Nice, France) (Nice, September 2018). The central theme of JMLC is to discuss new advances and exchange ideas regarding lung cancer. Notably, the talks covered different topics on new therapeutic strategies (targeted therapy and immuno-oncology), molecular and cellular biology, biomarkers, and the epidemiology of lung cancer. Special attention was also given to lung cancer in elderly patients. The articles published in this Special Issue covered subjects such as the assessment of new biomarkers and new approaches for the early detection of lung cancer, epidemiological data, and emphasized a place for the newly characterized cellular pathways in lung cancer, which opens room for therapeutic perspectives for lung cancer patients.

This Special Issue of Cancers (Basel) is mainly dedicated to selecting papers from the talks given during the first Joint Meeting on Lung Cancer (JMLC) between the MD Anderson Cancer Center (Houston, Texas USA) and the Hospital University Federation (HUF) OncoAge (University Côte d'Azur, Nice, France) (Nice, September 2018). The central theme of JMLC is to discuss new advances and exchange ideas regarding lung cancer. Notably, the talks covered different topics on new therapeutic strategies (targeted therapy and immuno-oncology), molecular and cellular biology, biomarkers, and the epidemiology of lung cancer. Special attention was also given to lung cancer in elderly patients. The articles published in this Special Issue covered subjects such as the assessment of new biomarkers and new approaches for the early detection of lung cancer, epidemiological data, and emphasized a place for the newly characterized cellular pathways in lung cancer, which opens room for therapeutic perspectives for lung cancer patients.

Endobronchial ultrasonography (EBUS) is an exciting new diagnostic tool that has added significantly to the diagnosis and staging of lung cancer and other thoracic diseases. This book is co-authored by one of the technology's pioneers and will help the reader to use EBUS to diagnose and stage lung cancer and a variety of different tumours of the chest region. Endobronchial Ultrasonography covers all of the standard techniques and the new developments involved in EBUS as it combines two common procedures, bronchoscopy and real-time ultrasonography. This allows physicians to obtain precise biopsies of lymph nodes and masses within the chest cavity. Over 250 high quality colour digital images are featured throughout the book to illustrate the different applications of EBUS, complemented by specific case studies. This book is accompanied by a companion website featuring over 30 video clips cited in the text.

This book provides health professionals and scientists with a comprehensive overview of the mesothelioma - an asbestos induced malignancy. It includes chapters on epidemology, diagnosis, histopathology, radiology, surgery, chemotherapy, immune therapy, and radiotherapy as well as the molecular biology and future therapies.

This book reviews the current applications of molecular tools in cytopathology and provides a concise handbook for those who provide care in this era of personalized medicine. Specifically, the text provides a comprehensive and concise review of the emerging molecular tests available clinically in different subspecialities of diagnostic pathology. It reviews the current data of molecular testing already applied in cytopathology, discusses some of the biomarkers with potential utility in cytopathology in the near future and reviews the technical challenges in applying and validating molecular tools in liquid-based cytologic materials. Molecular Cytopathology will serve as a valuable resource for cytopathologists, cytotechnologists, pathology trainees, and clinicians with an interest in molecular applications in cytopathology.

This book illustrates various aspects of cancer cell metabolism, including metabolic regulation in solid tumours vs. non-solid tumours, the molecular pathways involved in its metabolism, and the role of the tumour microenvironment in the regulation of cancer cell metabolism. It summarizes the complexity of cancer cell metabolism in terms of the switch from anaerobic to aerobic glycolysis and how mitochondrial damage promotes aerobic glycolysis in cancer cells. The respective chapters provide the latest information on the metabolic remodelling of cancer cells and elucidate the important role of the signalling pathways in reprogramming of cancer cell metabolism. In addition, the book highlights the role of autophagy in cancer cell metabolism, and how metabolic crosstalk between cancer cells and cancer-associated fibroblasts promotes cancer cell progression. In closing, it summarizes recent advancements in drug development through targeting cancer metabolism.

TNM Classification of Malignant Tumours, 7th Edition provides the latest, internationally agreed-upon standards to describe and categorize cancer stages and progression. Published in affiliation with the International Union Against Cancer (UICC), this authoritative guide contains important updated organ-specific classifications that oncologists and other professionals who manage patients with cancer need to accurately classify tumours for staging, prognosis and treatment. The major alterations addressed in the 7th Edition concern carcinomas of the oesophagus and the gastroesophageal junction, stomach, lung, appendix, biliary tract, skin, and prostate. In addition, there are several entirely new classifications: gastrointestinal carcinoids (neuroendocrine tumours) gastrointestinal stromal tumour upper aerodigestive mucosal melanoma Merkel cell carcinoma uterine sarcomas intrahepatic cholangiocarcinoma adrenal cortical carcinoma. A new approach has also been adopted to separate anatomical stage groupings from prognostic groupings in which other prognostic factors are added to T, N, and M categories. These new prognostic groupings, as well as the traditional anatomical groupings, are presented for oesophageal and prostate carcinomas. Visit www.wileyanduicc.com for more information about the International Journal of Cancer and our other UICC book titles

This book illustrates the importance of the Natural Biometabolites, which offer a rich reservoir of candidate compounds for drug discovery in the battle against cancer. Recent research and development efforts concerning anti-cancer drugs derived from natural products have led to the identification of numerous candidate molecules that inhibit cancer cell proliferation and metastasis using a variety of mechanisms. Given its scope, the book offers a valuable resource for cancer biologists and general oncologists alike, while also benefitting research professionals in Science, Nursing, Medicine, Biochemistry, Genetics and Bioscience who wish to understand the fundamentals of prognosis and prediction in tumorigenesis. Moreover, the book provides an essential platform for understanding drug resistance mechanisms and combatting the growing menace of multidrug resistance.